Overview of Postmarketing Drug Safety Reporting Requirements - REdI 2020

FDA provides a regulatory foundation related to postmarketing drug safety reporting requirements and highlights the importance of submitting accurate, reliable, and timely safety data to FDA.

Presenter:
Kelley M. Simms
CDR, USPHS Regulatory Policy Analyst
Office of Surveillance and Epidemiology (OSE) | CDER
_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.

Upcoming training and free continuing education credits: https://www.fda.gov/cdersbia

CDER SBIA 2020 Playlist:    • 2020 CDER Small Business and Industry...  
LinkedIn:   / cder-small-business-and-industry-assistance  
Training resources: https://www.fda.gov/cderbsbialearn

Twitter:   / fda_drug_info  

CDER small business e-mail update subscription: https://updates.fda.gov/subscriptionm...

Email: [email protected]
Phone: (301) 796-6707 I (866) 405-5367